SAN DIEGO, Nov. 11 /PRNewswire/ -- Accumetrics, Inc. has announced the appointment of John J. Young, MD as Chief Medical Officer for the company. Dr. Young will serve in a part-time capacity in addition to his current appointment as Professor of Medicine and Director of the Cardiovascular Innovations Program at The Ohio State University in Columbus, Ohio. Dr. Young will serve as the main liaison to practicing clinicians, as well as coordinating ongoing research efforts and educational strategies.
"We are very pleased to welcome John to Accumetrics," said Timothy Still, President and CEO of The Company. "We look forward to leveraging his unique experience as a clinical investigator, as well as clinical expertise to continue to grow our Company."
Prior to joining The Ohio State University Medical Center, Dr. Young was the Co-Director of Cardiovascular Research & Education at the Swedish Heart & Vascular Institute in Seattle, Washington. Prior positions included Associate Director of the Lindner Center for Research & Education, and Director of Interventional Services at the Ohio Heart & Vascular Center, both in Cincinnati, Ohio. Dr. Young received his M.D. from The Ohio State University College of Medicine, where he completed both his Residency and Fellowship training. He also holds a Bachelor of Science degree in chemistry, with honors, from Wright State University, Dayton, OH. Finally, Dr. Young has received the distinction of being one of the "Best Doctors in America," and is a lifetime member of "Who's Who in Medicine & Healthcare."
About Accumetrics (http://www.accumetrics.com)
Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.
Accumetrics' VerifyNow(R) System is the first rapid and easy to use platform for measuring an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix(R), ReoPro(R), and Integrilin(R), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions.
The Accumetrics logo and VerifyNow are registered trademarks of
Accumetrics, Inc., ReoPro is a registered trademark of Centocor, Inc.
Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix
is a registered trademark of Sanofi-Aventis.
Lippert/Heilshorn & Associates
Copyright©2008 PR Newswire.
All rights reserved